The present invention describes methods for treating inflammatory disorders of the gastrointestinal tract, including but not limited to Inflammatory Bowel Disease (IBD), Crohns Disease (CD), Ulcerative Colitis (UC) and/or medically refractory ulcerative colitis (MR-UC) using anti-IFNG therapy. The present invention also describes a process for patient risk stratification.